NEWS Oncoscience signs contract with YM Biosciences Inc. ByOncoscience 15. November 200317. July 2025 Read the press release Download: >> press_release_YM_Biosciences (.pdf 28kB) Ähnliche Beiträge
NEWS Publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine. ByOncoscience 17. November 201717. July 2025
NEWS The European Medicines Agency, EMEA, concludes its formal validation of the marketing authorization application for Theraloc® (Nimotuzumab) positively ByOncoscience 26. October 200717. July 2025
NEWS YM BioSciences’ EGFr antibody receives EU orphan drug designation through Oncoscience AG, its European partner ByOncoscience 10. August 200417. July 2025
NEWS YM BioSciences and Oncoscience Report Response Rate of 35.3% in Pediatric Glioma ByOncoscience 1. March 200517. July 2025
NEWS YM Biosciences and Oncoscience AG achieve clinical milestone ByOncoscience 10. January 200517. July 2025
NEWS Oncoscience AG receives EU orphan drug status for the EGFR monoclonal antibody Nimotuzumab (Theraloc®) for the treatment of pancreatic cancer. ByOncoscience 22. April 200817. July 2025
